Indivior Pharmaceuticals Inc Financials
This page shows Indivior Pharmaceuticals Inc (INDV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Indivior Pharmaceuticals Inc generated $1.2B in revenue in fiscal year 2024.
Indivior Pharmaceuticals Inc's EBITDA was $67.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
Indivior Pharmaceuticals Inc generated $7.0M in free cash flow in fiscal year 2024, representing cash available after capex.
Indivior Pharmaceuticals Inc reported $7.0M in net income in fiscal year 2024.
Indivior Pharmaceuticals Inc earned $0.05 per diluted share (EPS) in fiscal year 2024.
Indivior Pharmaceuticals Inc held $319.0M in cash against $315.0M in long-term debt as of fiscal year 2024.
Indivior Pharmaceuticals Inc had 137M shares outstanding in fiscal year 2024.
Indivior Pharmaceuticals Inc's gross margin was 80.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs.
Indivior Pharmaceuticals Inc's operating margin was 3.2% in fiscal year 2024, reflecting core business profitability.
Indivior Pharmaceuticals Inc's net profit margin was 0.6% in fiscal year 2024, showing the share of revenue converted to profit.
Indivior Pharmaceuticals Inc invested $107.0M in research and development in fiscal year 2024.
Indivior Pharmaceuticals Inc spent $173.0M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
Indivior Pharmaceuticals Inc invested $29.0M in capex in fiscal year 2024, funding long-term assets and infrastructure.
INDV Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|
| Revenue | $314.0M+4.0% | $302.0M+13.5% | $266.0M |
| Cost of Revenue | $83.0M+59.6% | $52.0M+18.2% | $44.0M |
| Gross Profit | $230.0M-8.0% | $250.0M+13.1% | $221.0M |
| R&D Expenses | $33.0M+57.1% | $21.0M-4.5% | $22.0M |
| SG&A Expenses | $155.0M-1.9% | $158.0M+19.7% | $132.0M |
| Operating Income | $43.0M-40.3% | $72.0M+9.1% | $66.0M |
| Interest Expense | $9.0M0.0% | $9.0M0.0% | $9.0M |
| Income Tax | -$5.0M-111.4% | $44.0M+300.0% | $11.0M |
| Net Income | $42.0M+133.3% | $18.0M-61.7% | $47.0M |
| EPS (Diluted) | $0.33+135.7% | $0.14-63.2% | $0.38 |
INDV Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|
| Total Assets | $1.4B-2.5% | $1.5B+5.6% | $1.4B |
| Current Assets | $922.0M-3.0% | $951.0M+7.7% | $883.0M |
| Cash & Equivalents | $445.0M-12.7% | $510.0M+37.1% | $372.0M |
| Inventory | $155.0M+4.0% | $149.0M-8.6% | $163.0M |
| Accounts Receivable | $259.0M+7.9% | $240.0M-1.2% | $243.0M |
| Goodwill | $2.0M | N/A | N/A |
| Total Liabilities | $1.6B-5.0% | $1.7B+3.0% | $1.7B |
| Current Liabilities | $965.0M-8.6% | $1.1B+5.1% | $1.0B |
| Long-Term Debt | $304.0M-1.3% | $308.0M-1.0% | $311.0M |
| Total Equity | -$207.0M+19.5% | -$257.0M+9.8% | -$285.0M |
| Retained Earnings | -$346.0M+10.8% | -$388.0M+4.4% | -$406.0M |
INDV Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | $75.0M |
| Capital Expenditures | N/A | N/A | $5.0M |
| Free Cash Flow | N/A | N/A | $70.0M |
| Investing Cash Flow | N/A | N/A | -$5.0M |
| Financing Cash Flow | N/A | N/A | -$17.0M |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | $11.0M |
INDV Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|
| Gross Margin | 73.3%-9.5pp | 82.8%-0.3pp | 83.1% |
| Operating Margin | 13.7%-10.2pp | 23.8%-1.0pp | 24.8% |
| Net Margin | 13.4%+7.4pp | 6.0%-11.7pp | 17.7% |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | 3.0%+1.7pp | 1.2%-2.2pp | 3.4% |
| Current Ratio | 0.96+0.1 | 0.90+0.0 | 0.88 |
| Debt-to-Equity | -1.47-0.3 | -1.20-0.1 | -1.09 |
| FCF Margin | N/A | N/A | 26.3% |
Note: Shareholder equity is negative (-$337.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.90), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Financial Health Signals
Bankruptcy risk indicator. Above 2.99 = safe, below 1.81 = distress.
Operating cash flow vs net income. Above 1.0x = cash-backed earnings.
Operating income vs interest expense. Above 5x = safe, below 2x = risky.
Similar Companies
Frequently Asked Questions
What is Indivior Pharmaceuticals Inc's annual revenue?
Indivior Pharmaceuticals Inc (INDV) reported $1.2B in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Indivior Pharmaceuticals Inc profitable?
Yes, Indivior Pharmaceuticals Inc (INDV) reported a net income of $7.0M in fiscal year 2024, with a net profit margin of 0.6%.
What is Indivior Pharmaceuticals Inc's earnings per share (EPS)?
Indivior Pharmaceuticals Inc (INDV) reported diluted earnings per share of $0.05 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Indivior Pharmaceuticals Inc's EBITDA?
Indivior Pharmaceuticals Inc (INDV) had EBITDA of $67.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Indivior Pharmaceuticals Inc have?
As of fiscal year 2024, Indivior Pharmaceuticals Inc (INDV) had $319.0M in cash and equivalents against $315.0M in long-term debt.
What is Indivior Pharmaceuticals Inc's gross margin?
Indivior Pharmaceuticals Inc (INDV) had a gross margin of 80.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Indivior Pharmaceuticals Inc's operating margin?
Indivior Pharmaceuticals Inc (INDV) had an operating margin of 3.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Indivior Pharmaceuticals Inc's net profit margin?
Indivior Pharmaceuticals Inc (INDV) had a net profit margin of 0.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Indivior Pharmaceuticals Inc's free cash flow?
Indivior Pharmaceuticals Inc (INDV) generated $7.0M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Indivior Pharmaceuticals Inc's operating cash flow?
Indivior Pharmaceuticals Inc (INDV) generated $36.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Indivior Pharmaceuticals Inc's total assets?
Indivior Pharmaceuticals Inc (INDV) had $1.3B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Indivior Pharmaceuticals Inc's capital expenditures?
Indivior Pharmaceuticals Inc (INDV) invested $29.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Indivior Pharmaceuticals Inc spend on research and development?
Indivior Pharmaceuticals Inc (INDV) invested $107.0M in research and development during fiscal year 2024.
Does Indivior Pharmaceuticals Inc buy back shares?
Yes, Indivior Pharmaceuticals Inc (INDV) spent $173.0M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Indivior Pharmaceuticals Inc have outstanding?
Indivior Pharmaceuticals Inc (INDV) had 137M shares outstanding as of fiscal year 2024.
What is Indivior Pharmaceuticals Inc's current ratio?
Indivior Pharmaceuticals Inc (INDV) had a current ratio of 0.90 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Indivior Pharmaceuticals Inc's debt-to-equity ratio?
Indivior Pharmaceuticals Inc (INDV) had a debt-to-equity ratio of -0.93 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Indivior Pharmaceuticals Inc's return on assets (ROA)?
Indivior Pharmaceuticals Inc (INDV) had a return on assets of 0.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Indivior Pharmaceuticals Inc's debt-to-equity ratio negative or unusual?
Indivior Pharmaceuticals Inc (INDV) has negative shareholder equity of -$337.0M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Indivior Pharmaceuticals Inc's Altman Z-Score?
Indivior Pharmaceuticals Inc (INDV) has an Altman Z-Score of 1.97, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress.
Are Indivior Pharmaceuticals Inc's earnings high quality?
Indivior Pharmaceuticals Inc (INDV) has an earnings quality ratio of 5.14x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.
Can Indivior Pharmaceuticals Inc cover its interest payments?
Indivior Pharmaceuticals Inc (INDV) has an interest coverage ratio of 1.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.